Duality Biotherapeutics, Inc. (FRA:4ZB)

Market Cap	1.54B -49.7%
Revenue (ttm)	108.51M -61.2%
Net Income	-185.36M
EPS	-2.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	17.20
Previous Close	19.30
Day's Range	17.20 - 17.20
52-Week Range	17.20 - 39.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 266
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4ZB

Financial Performance

In 2025, Duality Biotherapeutics's revenue was 1.85 billion, a decrease of -4.61% compared to the previous year's 1.94 billion. Losses were -2.59 billion, 147.0% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error